Literature DB >> 21739165

Immunotherapy for tauopathies.

Jiaping Gu1, Einar M Sigurdsson.   

Abstract

Pathological tau protein is found in Alzheimer's disease and related tauopathies. The protein is hyperphosphorylated and/or mutated which leads to aggregation and neurotoxicity. Because cognitive functions correlate well with the degree of tau pathology, clearing these aggregates is a promising therapeutic approach. Studies pioneered by our laboratory and confirmed by others have shown that both active and passive immunizations targeting disease-related tau epitopes successfully reduce tau aggregates in vivo and slow or prevent behavioral impairments in mouse models of tauopathy. Here, we summarize recent advances in this new field.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21739165      PMCID: PMC3265133          DOI: 10.1007/s12031-011-9576-5

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  48 in total

1.  Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization.

Authors:  J-M Orgogozo; S Gilman; J-F Dartigues; B Laurent; M Puel; L C Kirby; P Jouanny; B Dubois; L Eisner; S Flitman; B F Michel; M Boada; A Frank; C Hock
Journal:  Neurology       Date:  2003-07-08       Impact factor: 9.910

2.  Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice.

Authors:  Pritam Das; Victor Howard; Nicole Loosbrock; Dennis Dickson; M Paul Murphy; Todd E Golde
Journal:  J Neurosci       Date:  2003-09-17       Impact factor: 6.167

Review 3.  Mutations causing neurodegenerative tauopathies.

Authors:  Michel Goedert; Ross Jakes
Journal:  Biochim Biophys Acta       Date:  2005-01-03

Review 4.  Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  Curr Alzheimer Res       Date:  2009-10       Impact factor: 3.498

5.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

Authors:  Eliezer Masliah; Edward Rockenstein; Anthony Adame; Michael Alford; Leslie Crews; Makoto Hashimoto; Peter Seubert; Michael Lee; Jason Goldstein; Tamie Chilcote; Dora Games; Dale Schenk
Journal:  Neuron       Date:  2005-06-16       Impact factor: 17.173

6.  Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

Authors:  J Lewis; D W Dickson; W L Lin; L Chisholm; A Corral; G Jones; S H Yen; N Sahara; L Skipper; D Yager; C Eckman; J Hardy; M Hutton; E McGowan
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

7.  Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice.

Authors:  Elena M Ribé; Mar Pérez; Berta Puig; Ignasi Gich; Filip Lim; Mar Cuadrado; Teresa Sesma; Silvia Catena; Belén Sánchez; María Nieto; Pilar Gómez-Ramos; M Asunción Morán; Felipe Cabodevilla; Lluis Samaranch; Lourdes Ortiz; Alberto Pérez; Isidro Ferrer; Jesús Avila; Teresa Gómez-Isla
Journal:  Neurobiol Dis       Date:  2005-08-24       Impact factor: 5.996

8.  Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology.

Authors:  Manuela Polydoro; Christopher M Acker; Karen Duff; Pablo E Castillo; Peter Davies
Journal:  J Neurosci       Date:  2009-08-26       Impact factor: 6.167

9.  Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice.

Authors:  Andreas Muhs; David T Hickman; Maria Pihlgren; Nathalie Chuard; Valérie Giriens; Carine Meerschman; Ingrid van der Auwera; Fred van Leuven; Masae Sugawara; Marie-Catherine Weingertner; Burkhard Bechinger; Ruth Greferath; Nadine Kolonko; Luitgard Nagel-Steger; Detlev Riesner; Roscoe O Brady; Andrea Pfeifer; Claude Nicolau
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-21       Impact factor: 11.205

10.  Transmission and spreading of tauopathy in transgenic mouse brain.

Authors:  Florence Clavaguera; Tristan Bolmont; R Anthony Crowther; Dorothee Abramowski; Stephan Frank; Alphonse Probst; Graham Fraser; Anna K Stalder; Martin Beibel; Matthias Staufenbiel; Mathias Jucker; Michel Goedert; Markus Tolnay
Journal:  Nat Cell Biol       Date:  2009-06-07       Impact factor: 28.824

View more
  18 in total

1.  Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models.

Authors:  Christopher M Acker; Stefanie K Forest; Ray Zinkowski; Peter Davies; Cristina d'Abramo
Journal:  Neurobiol Aging       Date:  2012-06-21       Impact factor: 4.673

Review 2.  Tau immunotherapy and imaging.

Authors:  Einar M Sigurdsson
Journal:  Neurodegener Dis       Date:  2013-09-11       Impact factor: 2.977

Review 3.  The TRPA1 channel in migraine mechanism and treatment.

Authors:  S Benemei; C Fusi; Gabriela Trevisan; Pierangelo Geppetti
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

4.  Could immunomodulation be used to prevent prion diseases?

Authors:  Thomas Wisniewski; Fernando Goñi
Journal:  Expert Rev Anti Infect Ther       Date:  2012-03       Impact factor: 5.091

Review 5.  A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.

Authors:  Michael G Agadjanyan; Nikolai Petrovsky; Anahit Ghochikyan
Journal:  Alzheimers Dement       Date:  2015-07-17       Impact factor: 21.566

Review 6.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

Review 7.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

8.  Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human α-synuclein: feasibility study.

Authors:  Anahit Ghochikyan; Irina Petrushina; Hayk Davtyan; Armine Hovakimyan; Tommy Saing; Arpine Davtyan; David H Cribbs; Michael G Agadjanyan
Journal:  Neurosci Lett       Date:  2013-12-19       Impact factor: 3.046

9.  Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AβPP(L/S) transgenic mice.

Authors:  Thuy-Vi V Nguyen; Lin Shen; Lilith Vander Griend; Lisa N Quach; Nadia P Belichenko; Nay Saw; Tao Yang; Mehrdad Shamloo; Tony Wyss-Coray; Stephen M Massa; Frank M Longo
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

10.  C-Terminally Truncated Forms of Tau, But Not Full-Length Tau or Its C-Terminal Fragments, Are Released from Neurons Independently of Cell Death.

Authors:  Daniel Kanmert; Adam Cantlon; Christina R Muratore; Ming Jin; Tiernan T O'Malley; Gloria Lee; Tracy L Young-Pearse; Dennis J Selkoe; Dominic M Walsh
Journal:  J Neurosci       Date:  2015-07-29       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.